TW201938177A - 產生富含腫瘤抗原特異性ｔ細胞的腫瘤浸潤淋巴球（ｔｉｌ）產物之方法 - Google Patents
產生富含腫瘤抗原特異性ｔ細胞的腫瘤浸潤淋巴球（ｔｉｌ）產物之方法 Download PDFInfo
- Publication number
- TW201938177A TW201938177A TW108100760A TW108100760A TW201938177A TW 201938177 A TW201938177 A TW 201938177A TW 108100760 A TW108100760 A TW 108100760A TW 108100760 A TW108100760 A TW 108100760A TW 201938177 A TW201938177 A TW 201938177A
- Authority
- TW
- Taiwan
- Prior art keywords
- til
- rna
- til population
- days
- population
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 263
- 230000008569 process Effects 0.000 title claims abstract description 50
- 206010028980 Neoplasm Diseases 0.000 title claims description 293
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 59
- 239000000427 antigen Substances 0.000 title claims description 49
- 102000036639 antigens Human genes 0.000 title claims description 49
- 108091007433 antigens Proteins 0.000 title claims description 49
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims abstract description 1091
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 123
- 230000001965 increasing effect Effects 0.000 claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 305
- 230000003321 amplification Effects 0.000 claims description 225
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 225
- 230000014509 gene expression Effects 0.000 claims description 193
- 102000004169 proteins and genes Human genes 0.000 claims description 177
- 108010002350 Interleukin-2 Proteins 0.000 claims description 146
- 102000000588 Interleukin-2 Human genes 0.000 claims description 146
- 230000002829 reductive effect Effects 0.000 claims description 105
- 210000004027 cell Anatomy 0.000 claims description 104
- 239000006143 cell culture medium Substances 0.000 claims description 98
- 125000003729 nucleotide group Chemical group 0.000 claims description 97
- 230000007704 transition Effects 0.000 claims description 94
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 claims description 89
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 claims description 89
- 239000002773 nucleotide Substances 0.000 claims description 87
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 83
- 102000017578 LAG3 Human genes 0.000 claims description 82
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 81
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims description 80
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 claims description 80
- 102000040945 Transcription factor Human genes 0.000 claims description 80
- 108091023040 Transcription factor Proteins 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 77
- 239000002609 medium Substances 0.000 claims description 72
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 51
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 51
- 238000001802 infusion Methods 0.000 claims description 50
- 102100030704 Interleukin-21 Human genes 0.000 claims description 49
- 101150030213 Lag3 gene Proteins 0.000 claims description 49
- 108010074108 interleukin-21 Proteins 0.000 claims description 49
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 45
- 102000003812 Interleukin-15 Human genes 0.000 claims description 44
- 108090000172 Interleukin-15 Proteins 0.000 claims description 44
- 238000004520 electroporation Methods 0.000 claims description 43
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims description 39
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 108020004414 DNA Proteins 0.000 claims description 33
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- -1 CSCR3 Proteins 0.000 claims description 31
- 102000053602 DNA Human genes 0.000 claims description 31
- 238000005138 cryopreservation Methods 0.000 claims description 31
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 230000001502 supplementing effect Effects 0.000 claims description 31
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 30
- 238000012258 culturing Methods 0.000 claims description 30
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 28
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 28
- 238000012545 processing Methods 0.000 claims description 28
- 238000012384 transportation and delivery Methods 0.000 claims description 27
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 25
- 239000012595 freezing medium Substances 0.000 claims description 25
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 24
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 24
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 24
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 22
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 22
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 22
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 22
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 21
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 21
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 20
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 20
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 20
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 20
- 102100026236 Interleukin-8 Human genes 0.000 claims description 20
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 20
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 20
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 19
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 19
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 19
- 238000012546 transfer Methods 0.000 claims description 19
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 18
- 230000003389 potentiating effect Effects 0.000 claims description 17
- 238000001890 transfection Methods 0.000 claims description 17
- 108020004459 Small interfering RNA Proteins 0.000 claims description 16
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 16
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 16
- 108700026244 Open Reading Frames Proteins 0.000 claims description 15
- 239000004055 small Interfering RNA Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 14
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 238000003752 polymerase chain reaction Methods 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 13
- 238000013518 transcription Methods 0.000 claims description 13
- 230000035897 transcription Effects 0.000 claims description 13
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 12
- 108700012434 CCL3 Proteins 0.000 claims description 12
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 12
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 12
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 12
- 230000001052 transient effect Effects 0.000 claims description 12
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 11
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims description 11
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims description 11
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 11
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 10
- 102100032912 CD44 antigen Human genes 0.000 claims description 10
- 108091033380 Coding strand Proteins 0.000 claims description 10
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 10
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 10
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims description 10
- 102000013462 Interleukin-12 Human genes 0.000 claims description 10
- 108010065805 Interleukin-12 Proteins 0.000 claims description 10
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims description 10
- 101150045565 Socs1 gene Proteins 0.000 claims description 10
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 10
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 10
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 10
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 10
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 10
- 108091008034 costimulatory receptors Proteins 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 8
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 241001663880 Gammaretrovirus Species 0.000 claims description 5
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 238000011109 contamination Methods 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims description 3
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 231100000590 oncogenic Toxicity 0.000 claims description 3
- 230000002246 oncogenic effect Effects 0.000 claims description 3
- 230000014828 interferon-gamma production Effects 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 15
- 238000007710 freezing Methods 0.000 claims 4
- 230000008014 freezing Effects 0.000 claims 4
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims 2
- 101100322911 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) aksF gene Proteins 0.000 claims 1
- 101150118781 icd gene Proteins 0.000 claims 1
- 230000008672 reprogramming Effects 0.000 abstract description 10
- 230000001976 improved effect Effects 0.000 abstract description 3
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 84
- 229920002477 rna polymer Polymers 0.000 description 65
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 41
- 238000013467 fragmentation Methods 0.000 description 35
- 238000006062 fragmentation reaction Methods 0.000 description 35
- 230000004048 modification Effects 0.000 description 33
- 238000012986 modification Methods 0.000 description 33
- 108091034117 Oligonucleotide Proteins 0.000 description 31
- 239000000203 mixture Substances 0.000 description 29
- 230000003247 decreasing effect Effects 0.000 description 27
- 239000000523 sample Substances 0.000 description 24
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 22
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 20
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 20
- 108091008874 T cell receptors Proteins 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 108010002586 Interleukin-7 Proteins 0.000 description 16
- 102000000704 Interleukin-7 Human genes 0.000 description 16
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 210000003071 memory t lymphocyte Anatomy 0.000 description 15
- 239000002679 microRNA Substances 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 230000009368 gene silencing by RNA Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 102000004388 Interleukin-4 Human genes 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000002018 overexpression Effects 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 108091070501 miRNA Proteins 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- 108050000299 Chemokine receptor Proteins 0.000 description 10
- 102000014736 Notch Human genes 0.000 description 10
- 108010070047 Notch Receptors Proteins 0.000 description 10
- 102000009410 Chemokine receptor Human genes 0.000 description 9
- 102000003814 Interleukin-10 Human genes 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 9
- 102000015696 Interleukins Human genes 0.000 description 9
- 108010063738 Interleukins Proteins 0.000 description 9
- 108091036407 Polyadenylation Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 9
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 108020005345 3' Untranslated Regions Proteins 0.000 description 7
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 6
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 6
- 101800001731 Notch 2 intracellular domain Proteins 0.000 description 6
- 102400000545 Notch 2 intracellular domain Human genes 0.000 description 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 6
- 102000056003 human IL15 Human genes 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229940047122 interleukins Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 210000002706 plastid Anatomy 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
- 102000008579 Transposases Human genes 0.000 description 5
- 108010020764 Transposases Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000007385 chemical modification Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- HBNBMOGARBJBHS-UHFFFAOYSA-N dimethylarsane Chemical compound C[AsH]C HBNBMOGARBJBHS-UHFFFAOYSA-N 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000010362 genome editing Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008093 supporting effect Effects 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 210000003563 lymphoid tissue Anatomy 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000005913 Notch signaling pathway Effects 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 238000011467 adoptive cell therapy Methods 0.000 description 3
- 108700025316 aldesleukin Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- 235000013928 guanylic acid Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000001400 myeloablative effect Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 2
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 108700031757 NKTR-214 Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940121413 bempegaldesleukin Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000003690 classically activated macrophage Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 102000052622 human IL7 Human genes 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229910052754 neon Inorganic materials 0.000 description 2
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000001370 static light scattering Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OAUKGFJQZRGECT-UUOKFMHZSA-N 8-Azaadenosine Chemical compound N1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OAUKGFJQZRGECT-UUOKFMHZSA-N 0.000 description 1
- 108020005176 AU Rich Elements Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010032795 CD8 receptor Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
- 108091007045 Cullin Ring E3 Ligases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 description 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
- 229940122117 Potassium channel agonist Drugs 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FHHZHGZBHYYWTG-INFSMZHSSA-N [(2r,3s,4r,5r)-5-(2-amino-7-methyl-6-oxo-3h-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate Chemical compound N1C(N)=NC(=O)C2=C1[N+]([C@H]1[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O1)O)=CN2C FHHZHGZBHYYWTG-INFSMZHSSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Dentistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614887P | 2018-01-08 | 2018-01-08 | |
| US62/614,887 | 2018-01-08 | ||
| US201862664034P | 2018-04-27 | 2018-04-27 | |
| US62/664,034 | 2018-04-27 | ||
| US201862669319P | 2018-05-09 | 2018-05-09 | |
| US62/669,319 | 2018-05-09 | ||
| US201862697921P | 2018-07-13 | 2018-07-13 | |
| US62/697,921 | 2018-07-13 | ||
| US201862734868P | 2018-09-21 | 2018-09-21 | |
| US62/734,868 | 2018-09-21 | ||
| US201862773715P | 2018-11-30 | 2018-11-30 | |
| US62/773,715 | 2018-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201938177A true TW201938177A (zh) | 2019-10-01 |
Family
ID=65324542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108100760A TW201938177A (zh) | 2018-01-08 | 2019-01-08 | 產生富含腫瘤抗原特異性ｔ細胞的腫瘤浸潤淋巴球（ｔｉｌ）產物之方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12104172B2 (https=) |
| EP (1) | EP3737743A1 (https=) |
| JP (2) | JP2021509586A (https=) |
| CN (2) | CN117866899B (https=) |
| AU (2) | AU2019205823C1 (https=) |
| BR (1) | BR112020013848A2 (https=) |
| CA (1) | CA3087771A1 (https=) |
| IL (1) | IL275724A (https=) |
| MA (1) | MA51636A (https=) |
| MX (1) | MX2020007046A (https=) |
| SG (1) | SG11202006541UA (https=) |
| TW (1) | TW201938177A (https=) |
| WO (1) | WO2019136456A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI920175B (zh) | 2020-12-02 | 2026-04-01 | 日商創革醫療科技有限公司 | 細胞層片製造用細胞培養器材、細胞層片製造用套組及細胞層片製造方法 |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US20230039976A1 (en) * | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| CN114615886A (zh) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | 细胞冷冻保存培养基 |
| JP2022553389A (ja) * | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用 |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| EP4146794A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US20240123067A1 (en) * | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| CA3207359A1 (en) * | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| WO2022166947A1 (zh) * | 2021-02-08 | 2022-08-11 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞的制备方法及其用途 |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| US20240365776A1 (en) | 2021-07-22 | 2024-11-07 | Iovance Biotherapeutics, Inc | Method for cryopreservation of solid tumor fragments |
| EP4471128A4 (en) * | 2022-01-29 | 2026-03-04 | Suzhou Grit Biotechnology Co Ltd | Modified tumor infiltrating lymphocyte and use thereof |
| EP4504220A1 (en) | 2022-04-06 | 2025-02-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| EP4522202A1 (en) | 2022-05-10 | 2025-03-19 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
| EP4289939A1 (en) * | 2022-06-10 | 2023-12-13 | Apeiron Biologics AG | Population of transfected immune cells and method for their production |
| CA3262929A1 (en) * | 2022-07-25 | 2024-02-01 | Sloan-Kettering Institute For Cancer Research | PREPARATION PROCESSES FOR ADOPTIVE CELL THERAPIES |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2024081791A2 (en) * | 2022-10-12 | 2024-04-18 | The Brigham And Women's Hospital, Inc. | Compositions and methods for maintaining a ccl3/ccl4 and ccr5 interaction program expressed during tumor progression |
| EP4623072A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| CN117025530B (zh) * | 2023-10-10 | 2023-12-12 | 再少年(北京)生物科技有限公司 | 用肿瘤坏死因子受体超家族激动剂扩增肿瘤浸润淋巴细胞（til）的方法 |
Family Cites Families (170)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7479269B2 (en) | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| ZA902710B (en) | 1989-05-22 | 1991-12-24 | Univ Georgia Res Found | Enzyme luminescence assay |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| ATE240394T1 (de) | 1992-10-23 | 2003-05-15 | Immunex Corp | Methoden zur herstellung löslicher, oligomerer proteine |
| GB9317380D0 (en) | 1993-08-20 | 1993-10-06 | Therexsys Ltd | Transfection process |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
| US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| AU2946295A (en) | 1994-06-27 | 1996-01-19 | Johns Hopkins University, The | Targeted gene delivery system |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| ES2185770T3 (es) | 1995-04-08 | 2003-05-01 | Lg Chemical Ltd | Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce. |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| RU2192281C2 (ru) | 1996-10-11 | 2002-11-10 | Бристол-Маерс Сквибб Компани | Способы и композиции для иммуномодуляции |
| US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
| US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| US6475994B2 (en) | 1998-01-07 | 2002-11-05 | Donald A. Tomalia | Method and articles for transfection of genetic material |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| WO2001009312A2 (en) | 1999-08-03 | 2001-02-08 | Sequitur, Inc. | Improvements in antisense oligomers, delivery of antisense oligomers, and identification of antisense oligomer targets |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| ES2382636T3 (es) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
| CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
| WO2004003142A2 (en) | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
| US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| ITMI20022118A1 (it) | 2002-10-04 | 2004-04-05 | Abiogen Pharma Spa | Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo. |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| AU2005302459A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| DK2650020T3 (en) | 2005-05-06 | 2017-01-16 | Providence Health & Services - Oregon | Trimeric OX40 immunoglobulin fusion protein and methods for applications. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| KR100650384B1 (ko) | 2005-09-12 | 2006-11-30 | 전남대학교산학협력단 | 성숙자연살해세포의 분화용 조성물 및 그 제조 방법 |
| US8206702B2 (en) | 2005-12-21 | 2012-06-26 | Sentoclone International Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
| EP1966370B1 (en) | 2005-12-21 | 2013-02-20 | SentoClone International AB | Method for obtaining T-lymphocytes |
| US8211424B2 (en) | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating malignant melanoma |
| US8007785B2 (en) | 2005-12-21 | 2011-08-30 | Sentoclone International Ab | Method for treating colon cancer with tumour-reactive T-lymphocytes |
| TWI466269B (zh) | 2006-07-14 | 2014-12-21 | Semiconductor Energy Lab | 非揮發性記憶體 |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| WO2008036841A2 (en) | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| US8859229B2 (en) | 2007-02-02 | 2014-10-14 | Yale University | Transient transfection with RNA |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| US20100136030A1 (en) | 2007-02-27 | 2010-06-03 | Lamhamedi-Cherradi Salah-Eddine | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| US7951365B2 (en) | 2007-06-27 | 2011-05-31 | Deifiera Falun Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types |
| EP2176288B1 (en) | 2007-07-10 | 2015-11-04 | Apogenix GmbH | Tnf superfamily collectin fusion proteins |
| EP2203746B1 (en) | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| WO2009045457A2 (en) | 2007-10-02 | 2009-04-09 | Rxi Pharmaceuticals Corp. | Tripartite rnai constructs |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
| EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
| US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
| DK2604693T3 (en) | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
| CA2746527A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| US20150320798A1 (en) | 2012-11-27 | 2015-11-12 | The Johns Hopkins University | Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity |
| WO2014085437A2 (en) | 2012-11-27 | 2014-06-05 | The Johns Hopkins University | Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| JP5844158B2 (ja) | 2009-01-09 | 2016-01-13 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | 三量体形成融合タンパク質 |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| US8383099B2 (en) * | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
| US8809050B2 (en) | 2009-12-08 | 2014-08-19 | Wilson Wolf Manufacturing | Methods of cell culture for adoptive cell therapy |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| WO2011109698A1 (en) | 2010-03-04 | 2011-09-09 | Rxi Pharmaceuticals Corporation | Formulations and methods for targeted delivery to phagocyte cells |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| BR112012024049A2 (pt) | 2010-03-24 | 2017-03-01 | Rxi Pharmaceuticals Corp | interferência de rna em indicações dérmicas e fibróticas |
| US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| SMT201700185T1 (it) | 2010-08-23 | 2017-05-08 | Univ Texas | Anticorpi anti-ox40 e metodi di uso degli stessi |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| KR20230084328A (ko) | 2010-12-30 | 2023-06-12 | 셀룰래리티 인코포레이티드 | 세포의 동결보존 및 캡슐화 방법 |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP2697367B1 (en) | 2011-04-13 | 2018-12-19 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| US20140234320A1 (en) | 2011-06-20 | 2014-08-21 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| CN107058101B (zh) | 2011-10-17 | 2021-06-01 | 麻省理工学院 | 细胞内传递 |
| AU2012324644B2 (en) | 2011-10-21 | 2014-08-28 | Cell Medica Limited | Device for the aseptic expansion of cells |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| SG11201407226WA (en) | 2012-05-18 | 2014-12-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| CN104411819B (zh) | 2012-06-11 | 2019-05-10 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
| US8959044B2 (en) | 2012-11-28 | 2015-02-17 | Linkedin Corporation | Recommender evaluation based on tokenized messages |
| RU2671897C2 (ru) | 2013-03-01 | 2018-11-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
| EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
| SMT201800503T1 (it) | 2013-03-18 | 2018-11-09 | Janssen Pharmaceuticals Inc | Anticorpi anti-cd (ox40) umanizzati e loro usi |
| MX2015015638A (es) | 2013-05-13 | 2016-10-28 | Cellectis | Metodos para diseñar celulas t altamente activas para inmunoterapia. |
| ES2897579T3 (es) * | 2013-06-10 | 2022-03-01 | Dana Farber Cancer Inst Inc | Métodos y composiciones para reducir la inmunosupresión por células tumorales |
| CN118562610A (zh) | 2013-06-24 | 2024-08-30 | 威尔逊沃夫制造公司 | 用于透气性细胞培养过程的封闭系统装置和方法 |
| JP6616295B2 (ja) | 2013-07-15 | 2019-12-04 | アメリカ合衆国 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
| WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
| WO2015084897A2 (en) | 2013-12-02 | 2015-06-11 | Mirimmune, Llc | Immunotherapy of cancer |
| AU2014364606A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| EP3686219A1 (en) | 2014-02-04 | 2020-07-29 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| JP2017511375A (ja) | 2014-03-20 | 2017-04-20 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 養子細胞療法のための腫瘍浸潤リンパ球 |
| WO2015157636A1 (en) * | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| AU2015273501B2 (en) | 2014-06-11 | 2021-01-21 | Polybiocept Gmbh | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
| EP3155426B1 (en) | 2014-06-13 | 2023-07-19 | Immudex ApS | General detection and isolation of specific cells by binding of labeled molecules |
| US9687510B2 (en) | 2014-09-04 | 2017-06-27 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| SMT202000562T1 (it) | 2014-09-16 | 2020-11-10 | Innate Pharma | Neutralizzazionne delle vie inibitorie nei linfociti |
| AU2014407539B2 (en) | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| US20170362556A1 (en) | 2014-12-09 | 2017-12-21 | Ge Healthcare Bio-Sciences Corp. | Systems and Methods for Aseptic Sampling |
| EP4372091A3 (en) | 2014-12-12 | 2024-07-31 | Tod M. Woolf | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| US9944894B2 (en) * | 2015-01-16 | 2018-04-17 | General Electric Company | Pluripotent stem cell expansion and passage using a rocking platform bioreactor |
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| US10544392B2 (en) | 2015-05-01 | 2020-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| FR3038324B1 (fr) | 2015-06-30 | 2020-10-30 | Lab Francais Du Fractionnement | Procede de cryoconservation de cellules a visee therapeutique |
| FR3040396A1 (fr) | 2015-06-30 | 2017-03-03 | Chu Nantes | Procede de cryoconservation de lymphocytes infiltrant la tumeur |
| SG10201912910PA (en) | 2015-07-09 | 2020-02-27 | Massachusetts Inst Technology | Delivery of materials to anucleate cells |
| US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| WO2017048614A1 (en) | 2015-09-15 | 2017-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| SG11201803330WA (en) | 2015-10-22 | 2018-05-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| CN108463547A (zh) | 2015-10-28 | 2018-08-28 | 生命技术股份公司 | 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群 |
| EP3397263B1 (en) * | 2015-12-30 | 2023-09-20 | Celgene Corporation | T lymphocyte production methods and t lymphocytes produced thereby |
| CN108779475A (zh) | 2016-01-12 | 2018-11-09 | Sqz生物技术公司 | 复合物的细胞内递送 |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| JP6872560B2 (ja) | 2016-05-06 | 2021-05-19 | エム． ウルフ、トッド | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| EP3248627B1 (en) | 2016-05-27 | 2020-02-26 | Fenwal, Inc. | Systems and methods for priming a fluid circuit |
| KR20190033066A (ko) * | 2016-06-24 | 2019-03-28 | 맥마스터 유니버시티 | 입양 세포 전달 및 종양붕괴 바이러스 병용 치료 |
| KR20190037243A (ko) | 2016-06-28 | 2019-04-05 | 지니우스 바이오테크놀로지 인코포레이티드 | 면역치료를 위한 티 세포 조성물 |
| CN106244538A (zh) | 2016-08-04 | 2016-12-21 | 英普乐孚生物技术(上海)有限公司 | 一种恶性腹水来源的til细胞的分离培养方法 |
| KR102561356B1 (ko) | 2016-09-14 | 2023-08-03 | 애브비 바이오테라퓨틱스 인크. | 항-pd-1 항체 및 이의 용도 |
| MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| CN106591232A (zh) | 2017-01-04 | 2017-04-26 | 安徽安龙基因医学检验所有限公司 | 一种高效的pd‑1‑cd8+t细胞的培养方法 |
| BR112019013940A2 (pt) * | 2017-01-06 | 2020-02-11 | Iovance Biotherapeutics, Inc. | Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica. |
| SG11201908271WA (en) | 2017-03-14 | 2019-10-30 | Juno Therapeutics Inc | Methods for cryogenic storage |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US20200224161A1 (en) | 2017-05-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| CN107384867B (zh) | 2017-08-04 | 2020-09-11 | 北京世纪劲得生物技术有限公司 | 一种肿瘤组织til细胞制备方法及专用培养基 |
-
2019
- 2019-01-08 SG SG11202006541UA patent/SG11202006541UA/en unknown
- 2019-01-08 MA MA051636A patent/MA51636A/fr unknown
- 2019-01-08 CN CN202311292767.1A patent/CN117866899B/zh active Active
- 2019-01-08 JP JP2020537589A patent/JP2021509586A/ja active Pending
- 2019-01-08 US US16/960,310 patent/US12104172B2/en active Active
- 2019-01-08 BR BR112020013848-7A patent/BR112020013848A2/pt unknown
- 2019-01-08 AU AU2019205823A patent/AU2019205823C1/en active Active
- 2019-01-08 WO PCT/US2019/012729 patent/WO2019136456A1/en not_active Ceased
- 2019-01-08 MX MX2020007046A patent/MX2020007046A/es unknown
- 2019-01-08 EP EP19703794.8A patent/EP3737743A1/en active Pending
- 2019-01-08 CA CA3087771A patent/CA3087771A1/en active Pending
- 2019-01-08 CN CN201980017442.8A patent/CN111836887A/zh active Pending
- 2019-01-08 TW TW108100760A patent/TW201938177A/zh unknown
-
2020
- 2020-06-29 IL IL275724A patent/IL275724A/en unknown
-
2023
- 2023-12-01 JP JP2023203723A patent/JP2024015137A/ja active Pending
-
2025
- 2025-09-25 AU AU2025238034A patent/AU2025238034A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI920175B (zh) | 2020-12-02 | 2026-04-01 | 日商創革醫療科技有限公司 | 細胞層片製造用細胞培養器材、細胞層片製造用套組及細胞層片製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117866899A (zh) | 2024-04-12 |
| SG11202006541UA (en) | 2020-08-28 |
| MX2020007046A (es) | 2020-09-07 |
| JP2024015137A (ja) | 2024-02-01 |
| AU2019205823B2 (en) | 2025-06-26 |
| AU2019205823C1 (en) | 2026-01-08 |
| CN117866899B (zh) | 2026-04-24 |
| MA51636A (fr) | 2020-11-18 |
| AU2019205823A1 (en) | 2020-07-30 |
| IL275724A (en) | 2020-08-31 |
| WO2019136456A1 (en) | 2019-07-11 |
| US20220204932A1 (en) | 2022-06-30 |
| BR112020013848A2 (pt) | 2020-12-01 |
| KR20200119242A (ko) | 2020-10-19 |
| JP2021509586A (ja) | 2021-04-01 |
| CA3087771A1 (en) | 2019-07-11 |
| CN111836887A (zh) | 2020-10-27 |
| AU2025238034A1 (en) | 2025-10-23 |
| EP3737743A1 (en) | 2020-11-18 |
| US12104172B2 (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201938177A (zh) | 產生富含腫瘤抗原特異性ｔ細胞的腫瘤浸潤淋巴球（ｔｉｌ）產物之方法 | |
| TWI833719B (zh) | 來自細針抽吸物及小活體組織切片之腫瘤浸潤淋巴細胞（ｔｉｌ）擴增 | |
| TWI831776B (zh) | 腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途 | |
| WO2019136459A1 (en) | Processes for generating til products enriched for tumor antigen-specific t-cells | |
| US11713446B2 (en) | Processes for generating TIL products enriched for tumor antigen-specific T-cells | |
| TW202039830A (zh) | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 | |
| TW202039829A (zh) | 改善之腫瘤反應性ｔ細胞的選擇 | |
| CN113748202B (zh) | 由液体肿瘤扩增肿瘤浸润淋巴细胞及其治疗用途 | |
| JP2021503885A (ja) | 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養 | |
| KR20210091212A (ko) | 항-pd-1 항체에 불응성인 nsclc 환자의 치료 | |
| KR102956273B1 (ko) | 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법 | |
| TWI916751B (zh) | 來自細針抽吸物及小活體組織切片之腫瘤浸潤淋巴細胞（ｔｉｌ）擴增 | |
| HK40109052A (zh) | 产生富含肿瘤抗原特异性t细胞的til产品的方法 | |
| HK40040250A (en) | Processes for generating til products enriched for tumor antigen-specific t-cells | |
| CN117940557A (zh) | 制备经修饰的肿瘤浸润性淋巴细胞的方法及其在过继性细胞治疗中的应用 | |
| HK40036034A (en) | Til expansion from fine needle aspirates and small biopsies | |
| HK40059000B (zh) | 用於产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途 |